Nuvalent, Inc.
HealthcareNASDAQ:NUVL · NASDAQ Global Select
-$0.18 today
Vol 7.10M · Avg 1.58M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.1%
avg 0.6%
ROIC
-31.4%
avg 88.3%
ROA
-30.1%
avg -85.1%
Analysis
ROA is currently the strongest return metric at -30.1% versus its period average of -85.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James R. Porter | Chief Executive Officer, President & Director | $1.14M | — | 50 | $324,879.00 | 0.44% |
Christopher D. Turner | Chief Medical Officer | $822,475.00 | — | 57 | $72,630.00 | 0.10% |
Alex Balcom | Chief Financial Officer & Treasurer | $753,791.00 | — | 42 | $131,637.00 | 0.18% |
Darlene Noci | Chief Development Officer | $741,317.00 | — | 48 | $6,091.00 | <0.01% |
Deborah Ann Miller | Chief Legal Officer & Secretary | $740,701.00 | — | 50 | $61,303.00 | 0.08% |
Chelcie Lister | Senior Director of Investor Relations & Corporate Communications | — | — | — | — | — |
Benjamin Lane | Chief Technical Operations Officer | — | — | — | $50,368.00 | 0.07% |
Henry Pelish | Chief Scientific Officer | — | — | 53 | $68,697.00 | 0.09% |
Joshua Horan | Senior Vice President of Chemistry | — | — | — | — | — |
Matthew Metivier | Senior Vice President of Human Resources | — | — | — | $1.38M | 1.87% |
Ruth Adams | Senior Vice President of Clinical Operations | — | — | — | — | — |
John Soglia | Senior Vice President of Translational Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
112
$36.94M
Net Sentiment
$36.94M
Net selling
Most Active
Noci Darlene
27 transactions
1–10 of 112
Analysis
Insiders reported 0 buys worth $0.00 and 112 sells worth $36.94M over the last 12 months. That adds up to net selling of $36.94M. Noci Darlene was the most active insider with 27 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A8 analysts |
| Net Income | N/A | N/A | N/A | N/A8 analysts |
| EBIT | N/A | N/A | N/A | N/A8 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.66B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.21B
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.43B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.70B
Metsera, Inc.
MTSR
$7.43B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.90B
Merus N.V.
MRUS
$6.83B
Abivax S.A.
NASDAQ:ABVX
$6.36B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.04B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.82B
Who manages NUVL?
Nuvalent, Inc. (NUVL) lists 12 active executives. The top listed executive is Chelcie Lister, Senior Director of Investor Relations & Corporate Communications.
Are NUVL insiders buying or selling?
Recent insider activity shows net selling of $20.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.